NeOnc Technologies Holdings is trading 6.28% up at $3.72 as investors focus on August 12 topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma.
- An August 10 filing confirmed the data presentation and investor call.
- Second-quarter loss widened as research and development spending increased nearly fourfold to $2.6 million; management emphasized the imminent clinical catalyst.
- The move appears company-specific rather than broader market momentum; volume and activity levels were not provided.